Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association ( <scp>HFA</scp> ), European Society of Cardiology ( <scp>ESC</scp> )
Wouter C. Meijers(University Medical Center Groningen), Rudolf A. de Boer(Erasmus MC), Antoni Bayés‐Genís(Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol), John G.F. Cleland(University of Glasgow), Thomas Mueller(University of Cambridge), Mark Richards(National University Health System), Alan S. Maisel(San Francisco VA Medical Center), James L. Januzzi(Harvard University), Andrew J.S. Coats(The Heart Research Institute), Petar Seferović, Alexandre Mebazaa(Marqueurs cardiovasculaires en situation de stress), Kenneth McDonald(University College Dublin), Christian Mueller(Immutep (Germany)), Johann Bauersachs(Medizinische Hochschule Hannover)
Cited by 178
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k